Rosetta Genomics Announces Agreement with Global Pharmaceutical Company
News Aug 05, 2014
Rosetta Genomics Ltd. has announced that it has signed an agreement with a global pharmaceutical company (GPC) in the area of Alzheimer's disease (AD) diagnostics.
Under the agreement, Rosetta will provide its microRNA profiling and other services to assist in the development of a microRNA-based diagnostic for the early detection of AD. Rosetta will leverage the GPC's expertise in AD as it is considered a pioneer in the development and commercialization of therapeutics for AD.
"Earlier diagnosis of Alzheimer's disease is critical to the development of new, effective therapeutics that can advance the standard-of-care for the treatment of AD. Currently, we are diagnosing AD patients too late in their disease to have an appreciable impact. We are delighted to be working with this global pharmaceutical company, one of the global leaders in Alzheimer's disease drug development, and look forward to using our cutting-edge microRNA expertise to advance development of an early stage diagnostic for this irreversible, progressive brain disease," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
"Our efforts in AD are another example of how, in addition to our current cancer testing services, we continue to explore ways to capitalize on our leading microRNA biomarker platform to respond to important unmet medical needs both within and outside of oncology," concluded Mr. Berlin.